Dr. Liggett is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
11100 Euclid Ave
Cleveland, OH 44106Phone+1 216-844-4960Fax+1 216-844-1947
Summary
- Dr. Thomas Liggett is a psychiatrist in Cleveland, OH and is affiliated with University Hospitals Cleveland Medical Center. He received his PhD in molecular biology and his medical degree from Touro University California College of Osteopathic Medicine and has been in practice 4 years. He specializes in addiction medicine and psychiatry and is an experienced researcher in multiple sclerosis, glioblastoma, pancreatic disease, and macular degeneration.
Education & Training
Case Western Reserve University/University Hospitals Cleveland Medical CenterFellowship, Addiction Psychiatry, 2019 - 2020- Case Western Reserve University/University Hospitals Cleveland Medical CenterResidency, Psychiatry, 2015 - 2019
Touro University CaliforniaClass of 2015, DO, MPH
Rush University Medical CenterPost-Doctoral Fellowship, 2007 - 2011
Northern Illinois UniversityPhD, Cell and molecular biology, biochemisty and biophysics, 2002 - 2007
Certifications & Licensure
OH State License 2019 - 2026- American Board of Psychiatry and Neurology Psychiatry
- National Acupuncture Detox AssociationAcupuncture Detox Specialist
Publications & Presentations
PubMed
- 29 citationsCross-Immunoreactivity between Bacterial Aquaporin-Z and Human Aquaporin-4: Potential Relevance to Neuromyelitis OpticaZhihua Ren, Yan Wang, Tao Duan, Jilpa Patel, Thomas Liggett
Journal of Immunology. 2012-11-01 - 64 citationsDNA methylation patterns in blood of patients with colorectal cancer and adenomatous colorectal polyps.Elisa Cassinotti, Joshua Melson, Thomas Liggett, Anatoliy A. Melnikov, Qilong Yi
International Journal of Cancer. 2012-09-01 - 47 citationsMethylation of death-associated protein kinase is associated with cetuximab and erlotinib resistanceTakenori Ogawa, Thomas Liggett, Anatoliy A. Melnikov, Constance L. Monitto, Daniela Kusuke
Cell Cycle. 2012-04-15
Professional Memberships
- Member
- Member
- Member
- Member
- American Academy of Addiction PsychiartyMember
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
